2004
DOI: 10.1016/s1083-8791(04)00067-9
|View full text |Cite
|
Sign up to set email alerts
|

Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma

Abstract: Previous work suggested that interleukin (IL)-2 can be used for eradicating residual disease in autologous grafts and for preventing recurrence. We report a phase II study of autologous peripheral blood stem cell transplantation with in vitro IL-2 incubation of peripheral blood stem cells and posttransplantation IL-2 in patients with recurrent or refractory non-Hodgkin lymphoma. Salvage chemotherapy consisted of ifosfamide and etoposide. Responding patients underwent autologous peripheral blood stem cell trans… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2006
2006
2008
2008

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 43 publications
0
2
0
Order By: Relevance
“…It is possible that the relatively brief, intensive course of IL-2 therapy in this study may not have provided sufficient duration of immunostimulation. Other groups have investigated the use of prolonged, lower-dose IL-2 immunotherapy with or without IL-2-activated lymphocytes beginning immediately after transplantation, 19 or 1 to 2 months after transplantation. 20 Although immunostimulatory changes of potential antitumor significance were reported, these researchers did not observe beneficial effects on relapse or survival in comparison with historical controls.…”
Section: Discussionmentioning
confidence: 99%
“…It is possible that the relatively brief, intensive course of IL-2 therapy in this study may not have provided sufficient duration of immunostimulation. Other groups have investigated the use of prolonged, lower-dose IL-2 immunotherapy with or without IL-2-activated lymphocytes beginning immediately after transplantation, 19 or 1 to 2 months after transplantation. 20 Although immunostimulatory changes of potential antitumor significance were reported, these researchers did not observe beneficial effects on relapse or survival in comparison with historical controls.…”
Section: Discussionmentioning
confidence: 99%
“…Although this is a widely used method (e.g. References [15][16][17]), this substitution of a control-arm estimator in a conditional power formula has the same problems as in the normal-outcomes and binomial-outcomes cases. Instead, we recommend using the estimator of the unconditional power, P 1S ( ;ˆ C ).…”
Section: Time-to-event Outcomesmentioning
confidence: 99%